Ausgewählte Publikationen

Aktuelle Publikationen finden Sie hier

 

Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna.

Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, Vossen MG, Winkler S, Thalhammer F. Clin Infect Dis. 2018 Aug 16;67(5):795-798. doi: 10.1093/cid/ciy279.

Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.

Kussmann M, Karer M, Obermueller M, Schmidt K, Barousch W, Moser D, Nehr M, Ramharter M, Poeppl W, Makristathis A, Winkler S, Thalhammer F, Burgmann H, Lagler H.

Emerg Microbes Infect. 2018 Dec 5;7(1):202. doi: 10.1038/s41426-018-0205-z.

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.

Kussmann M, Obermueller M, Berndl F, Reischer V, Veletzky L, Burgmann H, Poeppl W.

Sci Rep. 2018 Jun 25;8(1):9661. doi: 10.1038/s41598-018-28006-8.

Substantial diagnostic impact of blood culture independent molecular methods in bloodstream infections: Superior performance of PCR/ESI-MS.

Makristathis A, Harrison N, Ratzinger F, Kussmann M, Selitsch B, Forstner C, Hirschl AM, Burgmann H.

Sci Rep. 2018 Oct 30;8(1):16024. doi: 10.1038/s41598-018-34298-7.

Compatibility of linezolid with commercial peritoneal dialysis solutions.

Poeppl W, Rainer-Harbach E, Kussmann M, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Reznicek G.

Am J Health Syst Pharm. 2018 Oct 1;75(19):1467-1477. doi: 10.2146/ajhp170318.

Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases.

Harrison N, Poeppl W, Miksch M, Machold K, Kiener H, Aletaha D, Smolen JS, Forstner C, Burgmann H, Lagler H.

Vaccine. 2018 Aug 6;36(32 Pt B):4875-4879. doi: 10.1016/j.vaccine.2018.06.065. Epub 2018 Jul 3.

Substantial diagnostic impact of blood culture independent molecular methods in bloodstream infections: Superior performance of PCR/ESI-MS.

Makristathis A, Harrison N, Ratzinger F, Kussmann M, Selitsch B, Forstner C, Hirschl AM, Burgmann H.

Sci Rep. 2018 Oct 30;8(1):16024. doi: 10.1038/s41598-018-34298-7

Compatibility of linezolid with commercial peritoneal dialysis solutions.

Poeppl W, Rainer-Harbach E, Kussmann M, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Reznicek G.

Am J Health Syst Pharm. 2018 Oct 1;75(19):1467-1477. doi: 10.2146/ajhp170318.

Machine learning for fast identification of bacteraemia in SIRS patients treated on standard care wards: a cohort study.

Ratzinger F, Haslacher H, Perkmann T, Pinzan M, Anner P, Makristathis A, Burgmann H, Heinze G, Dorffner G.

Sci Rep. 2018 Aug 15;8(1):12233. doi: 10.1038/s41598-018-30236-9

Empirical antimicrobial treatment in haemato-/oncological patients with neutropenic sepsis.

Vossen MG, Milacek C, Thalhammer F.

ESMO Open. 2018 Jun 13;3(3):e000348. doi: 10.1136/esmoopen-2018-000348. eCollection 2018. Review

Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa.

Kussmann M, Hauer S, Pichler P, Reznicek G, Burgmann H, Poeppl W, Zeitlinger M, Wiesholzer M.

Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1091-1098. doi: 10.1007/s10096-018-3221-y. Epub 2018 Mar 15

Empirical antimicrobial treatment in haemato-/oncological patients with neutropenic sepsis.

Vossen MG, Milacek C, Thalhammer F.

ESMO Open. 2018 Jun 13;3(3):e000348. doi: 10.1136/esmoopen-2018-000348. eCollection 2018

Compatibility of linezolid with commercial peritoneal dialysis solutions.

Poeppl W, Rainer-Harbach E, Kussmann M, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Reznicek G.

Am J Health Syst Pharm. 2018 Oct 1;75(19):1467-1477. doi: 10.2146/ajhp170318

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.

Kussmann M, Obermueller M, Berndl F, Reischer V, Veletzky L, Burgmann H, Poeppl W.

Sci Rep. 2018 Jun 25;8(1):9661. doi: 10.1038/s41598-018-28006-8

Substantial diagnostic impact of blood culture independent molecular methods in bloodstream infections: Superior performance of PCR/ESI-MS.

Makristathis A, Harrison N, Ratzinger F, Kussmann M, Selitsch B, Forstner C, Hirschl AM, Burgmann H.

Sci Rep. 2018 Oct 30;8(1):16024. doi: 10.1038/s41598-018-34298-7

Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa.

Kussmann M, Hauer S, Pichler P, Reznicek G, Burgmann H, Poeppl W, Zeitlinger M, Wiesholzer M.

Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1091-1098. doi: 10.1007/s10096-018-3221-y. Epub 2018 Mar 15

Specific cholecystitis: An unusual presentation of extrapulmonary tuberculosis.

Veletzky L, Österreicher ZA, Mayer KA, Ba-Ssalamah A, Ramharter M, Winkler S.

Int J Infect Dis. 2018 Dec;77:16-17. doi: 10.1016/j.ijid.2018.09.010. Epub 2018 Sep 20

Lack of dermal penetration of topically applied gentamicin as pharmacokinetic evidence indicating insufficient efficacy.

Oesterreicher Z, Lackner E, Jäger W, Höferl M, Zeitlinger M.

J Antimicrob Chemother. 2018 Oct 1;73(10):2823-2829. doi: 10.1093/jac/dky274

Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.

Richter L, Schmid D, Kanitz EE, Zwazl I, Pöllabauer E, Jasinska J, Burgmann H, Kundi M, Wiedermann U.

PLoS One. 2019 Jan 10;14(1):e0210081. doi: 10.1371/journal.pone.0210081. eCollection 2019. Erratum in: PLoS One. 2019 Feb 21;14(2):e0212957.

Review: Epidemiology of Helicobacter pylori infection.

Leja M, Grinberga-Derica I, Bilgilier C, Steininger C.

Helicobacter. 2019 Sep;24 Suppl 1:e12635. doi: 10.1111/hel.12635.

Plasmid DNA contaminant in molecular reagents.

Wally N, Schneider M, Thannesberger J, Kastner MT, Bakonyi T, Indik S, Rattei T, Bedarf J, Hildebrand F, Law J, Jovel J, Steininger C.

Sci Rep. 2019 Feb 7;9(1):1652. doi: 10.1038/s41598-019-38733-1.

Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.

Tobudic S, Forstner C, Burgmann H, Lagler H, Steininger C, Traby L, Vossen MG, Winkler S, Thalhammer F.

Infection. 2019 Dec;47(6):1013-1020. doi: 10.1007/s15010-019-01354-x. Epub 2019 Sep 13

Minimal Reconstitution of Membranous Web Induced by a Vesicle-Peptide Sol-Gel Transition.

Ho JCS, Steininger C, Hiew SH, Kim MC, Reimhult E, Miserez A, Cho N, Parikh AN, Liedberg B.

Biomacromolecules. 2019 Apr 8;20(4):1709-1718. doi: 10.1021/acs.biomac.9b00081. Epub 2019 Mar 26.

Oxygen Management at the Microscale: A Functional Biochip Material with Long-Lasting and Tunable Oxygen Scavenging Properties for Cell Culture Applications.

Sticker D, Rothbauer M, Ehgartner J, Steininger C, Liske O, Liska R, Neuhaus W, Mayr T, Haraldsson T, Kutter JP, Ertl P.

ACS Appl Mater Interfaces. 2019 Mar 13;11(10):9730-9739. doi: 10.1021/acsami.8b19641. Epub 2019 Feb 26

Correction to: Real‑world experience with dalbavancin therapy in gram‑positive skin and soft tissue infection, bone and joint infection.

Tobudic S, Forstner C, Burgmann H, Lagler H, Steininger C, Traby L, Vossen MG, Winkler S, Thalhammer F.

Infection. 2019 Nov 18. doi: 10.1007/s15010-019-01372-9

Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions.

Kussmann M, Ferth A, Obermüller M, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Poeppl W, Reznicek G.

Sci Rep. 2019 Apr 24;9(1):6512. doi: 10.1038/s41598-019-42854-y.

Prevalence and Outcome of Secondary Hemophagocytic Lymphohistiocytosis Among SIRS Patients: Results from a Prospective Cohort Study.

Gualdoni GA, Hofmann GA, Wohlfarth P, Winkler HM, Winkler S, Haslacher H, Thalhammer R, Makristathis A, Ratzinger F, Burgmann H.

J Clin Med. 2019 Apr 19;8(4). pii: E541. doi: 10.3390/jcm8040541

Effect of Peritoneal Dialysis Fluids on Activity of Teicoplanin Against Methicillin-Resistant Staphylococcus aureus Biofilm.

Tobudic S, Kern S, Kussmann M, Forstner C, Burgmann H.

Perit Dial Int. 2019 May-Jun;39(3):293-294. doi: 10.3747/pdi.2018.00168

Rate and Predictors of Bacteremia in Afebrile Community-Acquired Pneumonia.

Forstner C, Patchev V, Rohde G, Rupp J, Witzenrath M, Welte T, Burgmann H, Pletz MW; CAPNETZ Study Group.

Chest. 2019 Oct 26. pii: S0012-3692(19)34102-9. doi: 10.1016/j.chest.2019.10.006

Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.

Venkatesan S, Myles PR, Bolton KJ, Muthuri SG, Al Khuwaitir T, Anovadiya AP, Azziz-Baumgartner E, Bajjou T, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Chinbayar T, Cilloniz C, Denholm JT, Dominguez SR, Duarte PAD, Dubnov-Raz G, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Higuera Iglesias AL, Hoeger PH, Hu XY, Islam QT, Jiménez MF, Keijzers G, Khalili H, Kusznierz G, Kuzman I, Langenegger E, Lankarani KB, Leo YS, Libster RP, Linko R, Madanat F, Maltezos E, Mamun A, Manabe T, Metan G, Mickiene A, Mikić D, Mohn KGI, Oliva ME, Ozkan M, Parekh D, Paul M, Rath BA, Refaey S, Rodríguez AH, Sertogullarindan B, Skręt-Magierło J, Somer A, Talarek E, Tang JW, To K, Tran D, Uyeki TM, Vaudry W, Vidmar T, Zarogoulidis P; PRIDE Consortium Investigators , Nguyen-Van-Tam JS.

J Infect Dis. 2019 Jul 17. pii: jiz152. doi: 10.1093/infdis/jiz152

Dalbavancin Dosage.

Tobudic S, Thalhammer F.

Clin Infect Dis. 2019 Apr 24;68(9):1608. doi: 10.1093/cid/ciy941

Zirconium Nitride Coating Reduced Staphylococcus epidermidis Biofilm Formation on Orthopaedic Implant Surfaces: An In Vitro Study.

Pilz M, Staats K, Tobudic S, Assadian O, Presterl E, Windhager R, Holinka J.

Clin Orthop Relat Res. 2019 Feb;477(2):461-466

Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions.

Kussmann M, Ferth A, Obermüller M, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Poeppl W, Reznicek G.

Sci Rep. 2019 Apr 24;9(1):6512. doi: 10.1038/s41598-019-42854-y

Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood.

Oesterreicher Z, Eberl S, Zeitlinger M.

Infection. 2019 Aug 1. doi: 10.1007/s15010-019-01346-x

Impact of different pathophysiological conditions on antimicrobial activity of glycopeptides in vitro.

Oesterreicher Z, Eberl S, Nussbaumer-Proell A, Peilensteiner T, Zeitlinger M.

Clin Microbiol Infect. 2019 Jun;25(6):759.e1-759.e7. doi: 10.1016/j.cmi.2018.09.004. Epub 2018 Sep 27